Pembrolizumab vs. chemotherapy in the first-line setting of PD-L1 ≥ 50% metastatic non-small cell lung cancer: a real-world cost-effectiveness analysis
Liu B, Parmar A, Luo J, Dai WF, Chan KKW. Eur J Health Econ. 2025; Oct 8 [Epub ahead of print].
Publications
Palliative care with tracheostomy or gastrostomy tube use and end-of-life quality and costs among patients with head and neck cancer
Fu R, Sutradhar R, Li Q, Villemure-Poliquin N, Chan KKW, Karam I, Hallet J, Eskander A. JAMA Otolaryngol Head Neck Surg. 2025; Sep 25 [Epub ahead of print].
Development of machine learning systems to predict cancer-related symptoms with validation across a health care system
Yuan B, Kabir M, He JC, Li Y, Grant B, Narine S, Welch M, Podolsky S, Liu N, Ajaj R, Zhan LJ, Fawzy A, Xu J, Zhang Y, Yu V, Xu W, Krishnan RG, Gallinger S, Chan KKW, Krzyzanowska MK, Truong T, Liu G, Grant RC. JCO Clin Cancer Inform. 2025; 9:e2500073. Epub 2025 Sep 25.
Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia
Hoang T, Cheung MC, Juurlink DN, Chan KKW, Lau C, Liu N, Abdel-Qadir H, Prica A, Hay AE, Vijenthira A, Mozessohn L. Br J Haematol. 2025; Aug 29 [Epub ahead of print].
Predicting chronic kidney disease after cisplatin treatment using population-level data
Grant RC, He JC, Liu N, Podolsky S, Notta F, Ghassemi M, Gallinger S, Knezevic A, Latcha S, Jaimes E, Kitchlu A, Chan K. JAMA Oncol. 2025; 11(10): 1179-1185.
Validity of using general and cancer-specific health administrative data to identify treatment exposures in adolescents and young adults with cancer: a population-based study using the IMPACT cohort
Guolla L, Lau C, Chan KKW, Nathan PC, Gupta S. Cancer Epidemiol. 2025; 98:102902. Epub 2025 Aug 9.
Patients with head and neck cancer and high health care costs: a population-based study
Villemure-Poliquin N, Fu R, Li Q, Ayoo K, Chan KKW, Karam I, Wright FC, Coburn NG, Hallet J, Eskander A. JAMA Otolaryngol Head Neck Surg. 2025; e251976. Epub 2025 Jul 17.
Real-world comparative effectiveness and safety of pertuzumab in patients with HER2+ metastatic breast cancer: a pan-Canadian population-based cohort study
Muñoz CE, Dai WF, Cheung WY, de Oliveira C, Pataky RE, Ding PQ, Tran DA, Aurangzeb Z, Nagamuthu C, Liu N, Lethbridge L, McClure C, Vriends K, Xiong H, Folkins C, Somayaji C, Peacock S, Alvi R, Turner D, O’Conaill C, McDonald T, Urquhart R, Kendell C, Dowden J, Strumpf E, Denburg A, Beca JM, Mercer RE, Tadrous M, Takhar P, Chan KKW; CanREValue Collaboration. Int J Cancer. 2025; Apr 23 [Epub ahead of print].
Trends in the cost and utilization of publicly reimbursed cancer medications dispensed as take-home treatments from 2017-2021
Garg R, Dumont T, McCormack D, Tadrous M, Campbell T, Chan K, Gomes T. Curr Oncol. 2025; 32(4):237.
Population-based analysis of the risk of mycobacterial infections associated with immune checkpoint inhibitors
Yan M, Hernandez A, Chan KK, Stanbrook MB, Blanchette PS, Johnston JC, Lee SM, Macdonald L, Richard-Greenblatt M, Marras TK, Brode SK. Clin Infect Dis. 2025: ciae626. Epub 2025 Jan 28.